ReviewDialogues in clinical neuroscience2014
Using biomarkers to predict treatment response in major depressive disorder: evidence from past and present studies.
Review in Dialogues in clinical neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- The establishment of the objective diagnostic markers and personalized medical intervention in patients with major depressive disorder: rationale and protocol.BMC psychiatry · 2016Trial
- Telomere length as a predictor of response to Pioglitazone in patients with unremitted depression: a preliminary study.Translational psychiatry · 2016Trial
- The Role of Extracellular Vesicles in Neuropsychiatric Disorders.Advanced pharmaceutical bulletin · 2025Review
- Insights for the Next Generation of Ketamine for the Treatment of Depressive Disorder.Journal of medicinal chemistry · 2025Review
- Reinforcement learning processes as forecasters of depression remission.Journal of affective disorders · 2025Article
- Challenges and Opportunities in Managing Geriatric Depression: The Role of Personalized Medicine and Age-Appropriate Therapeutic Approaches.Pharmaceutics · 2024Review
- Are There Biological Correlates of Response to Yoga-Based Interventions in Depression? A Critical Scoping Review.Brain sciences · 2024Article
- Sex matters: acute functional connectivity changes as markers of remission in late-life depression differ by sex.Molecular psychiatry · 2023Article
- Elevated serum leptin is associated with attenuated reward anticipation in major depressive disorder independent of peripheral C-reactive protein levels.Scientific reports · 2023Article
- Mental Activity as the Bridge between Neural Biomarkers and Symptoms of Psychiatric Illness.Clinical EEG and neuroscience · 2023Article
- Observational
- Effectiveness, cost-utility and physiological underpinnings of the FIBROWALK multicomponent therapy in online and outdoor format in individuals with fibromyalgia: Study protocol of a randomized, controlled trial (On&Out study).Frontiers in physiology · 2022Article
- Zebrafish as an Animal Model for Testing Agents with Antidepressant Potential.Life (Basel, Switzerland) · 2021Review
- Assessment of a Prediction Model for Antidepressant Treatment Stability Using Supervised Topic Models.JAMA network open · 2020Article
- Novel Treatment Targets Based on Insights in the Etiology of Depression: Role of IL-6 Trans-Signaling and Stress-Induced Elevation of Glutamate and ATP.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Poor management of hypertension is an important precipitating factor for the development of acute aortic dissection.Journal of clinical hypertension (Greenwich, Conn.) · 2019Article
- Robustness of testing procedures for confirmatory subpopulation analyses based on a continuous biomarker.Statistical methods in medical research · 2019Article
- Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient.The international journal of neuropsychopharmacology · 2018Review
- Understanding and Predicting Antidepressant Response: Using Animal Models to Move Toward Precision Psychiatry.Frontiers in psychiatry · 2018Review
- Neurocognitive performance as an endophenotype for mood disorder subgroups.Journal of affective disorders · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) is a heterogeneous condition with a variable response to a wide range of treatments. Despite intensive efforts, no biomarker has been identified to date that can reliably predict response or non-response to any form of treatment, nor has one been identified that can be used to identify those at high risk of developing treatment-resistant depression (ie, non-response to a sequence of treatments delivered for adequate duration and intensity). This manuscript reviews some past areas of research that have proved informative, such as studies using indexes of hypercortisolism or sleep disturbance, and more recent research findings using measures of inflammation and different indicators of regional cortical activation to predict treatment response. It is concluded that, although no method has yet been demonstrated to be sufficiently accurate to be applied in clinical practice, progress has been made. It thus seems likely that--at some point in the not-too-distant future--it will be possible to prospectively identify, at least for some MDD patients, the likelihood of response or non-response to cognitive therapy or various antidepressant medications.
Indexed as
Identifiers
25733957PMC4336922What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.